On May 22, METiS Pharmaceuticals-P declined 5.13% in regular trading, trading at 15.72 HKD/share, with trading volume of 15.79 million HKD. The stock has extended its multi-day pullback from its listing-day highs.

On the news front, METiS Pharmaceuticals, branded as the world's first AI drug delivery company to go public, debuted on the Hong Kong Stock Exchange on May 13 at an IPO price of 10.50 HKD, surging 173% on its first day. Since then, the stock has been in sustained retreat. The company remains in an early commercialization stage, having accumulated approximately 1.5 billion RMB in losses over the past three years with volatile revenue, leaving its growth outlook unproven. Additionally, some internationally placed shares carry no lock-up period, creating persistent profit-taking pressure. As initial new-listing enthusiasm accelerates its fade, the stock continues to face downward pressure.

METiS Pharmaceuticals is an AI-driven nanomaterial innovation biotech company focused on targeted drug delivery and discovery technologies, aiming to accelerate innovative therapies for patients across critical disease areas including oncology, metabolic disorders, autoimmune diseases, and neurodegenerative conditions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)